Daniel Lawton

This inventor holds 7 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Promentis Pharmaceuticals, Inc.. Active years: 2014-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Daniel Lawton. Retrieved from https://idiyas.com/inventor/daniel-lawton

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 3)

% Patents Active = 85.7

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 3.6

ph-index = 3

Forward Citations = 32(Granted Patents)

Company Filing History:

7 out of 9

Promentis Pharmaceuticals, Inc.

patents

Years Active: 2014-2021

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10961187 - Substituted N-acetyl-L-cysteine derivatives and related compounds (2021-03-30),

2. 10358414 - Substituted N-acetyl-L-cysteine derivatives and related compounds (2019-07-23),

3. 10112897 - Substituted N-acetyl-L-cysteine derivatives and related compounds (2018-10-30),

4. 9630937 - Substituted N-acetyl-L-cysteine derivatives and related compounds (2017-04-25),

5. 9457014 - Cysteine prodrugs (2016-10-04),

6. 9012674 - Ethyl (2R)-2-acetamido-3-(4-methylbenzoylsulfanyl)propanoate and uses thereof (2015-04-21),

7. 8624052 - S-t-butyl protected cysteine di-peptide analogs and related compounds (2014-01-07),

Title: The Innovative Contributions of Daniel Lawton

Introduction

Daniel Lawton is a notable inventor based in Bayside, Wisconsin, who has made significant contributions to the field of pharmaceuticals. With a total of seven patents to his name, Lawton's work focuses on developing novel compounds that have the potential to treat various diseases and conditions.

Latest Patents

Among his latest patents are the substituted N-acetyl-L-cysteine derivatives and related compounds. These innovative compounds are designed for the treatment of diseases involving the Central Nervous System (CNS). The conditions addressed by these compounds include schizophrenia, adrenoleukodystrophy, mitochondrial diseases such as Leigh syndrome, Alpers' disease, and MELAS, as well as Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.

Career Highlights

Daniel Lawton is currently associated with Promentis Pharmaceuticals, Inc., where he continues to advance his research and development efforts. His work is characterized by a commitment to improving therapeutic options for patients suffering from complex neurological conditions.

Collaborations

Lawton collaborates with esteemed colleagues, including Michael Neary and James Nieman, to further enhance the impact of his research. Their combined expertise contributes to the innovative environment at Promentis Pharmaceuticals.

Conclusion

Daniel Lawton's contributions to the field of pharmaceuticals through his innovative patents and collaborative efforts highlight his dedication to advancing medical science. His work has the potential to significantly improve the lives of individuals affected by challenging health conditions.

Profile summary based on public USPTO records.